Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27613683 | 0.91 | ALDH1A1 (0.43) | ALDH1A1HPGDTSHRUSP2EGLN2 | |
| SCHEMBL3111043 | 0.83 | ALDH1A1 (0.40) | ALDH1A1HPGDTSHRUSP2EGLN2 | |
| SCHEMBL8203208 | 0.78 | ACHE (0.57) | ALDH1A1HPGDTSHR | |
| SCHEMBL12160221 | 0.76 | FAAH (0.46) | ALDH1A1EGLN2EGLN1KDM4E | |
| SCHEMBL1745955 | 0.76 | HTT (0.51) | ALDH1A1HPGDUSP2EGLN2EGLN1 | |
| SCHEMBL14127245 | 0.76 | ALDH1A1 (0.39) | ALDH1A1HPGDTSHRUSP2EGLN2 | |
| SCHEMBL14127371 | 0.76 | ALDH1A1 (0.39) | ALDH1A1HPGDTSHREGLN2EGLN1 | |
| SCHEMBL3115401 | 0.76 | ALDH1A1 (0.35) | ALDH1A1HPGDTSHRUSP2KMT2A | |
| SCHEMBL14127451 | 0.74 | ACHE (0.41) | ALDH1A1HPGDTSHREGLN2EGLN1 | |
| SCHEMBL14108578 | 0.73 | SLC22A1 (0.43) | ALDH1A1HPGDTSHREGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7642289-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| EP-1572627-A1 | DRUGS FOR CHRONIC PAIN | Nicox S.A. (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004054965-A1 | DRUGS FOR CHRONIC PAIN | NICOX S.A. (FR) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | ALDH1A1 671/4885HPGD 628/4885TSHR 2361/4885 |
| US-20060270608-A1 | Drugs for chronic pain | OPRK1, OPRL1, OPRD1 | ALDH1A1 671/4885HPGD 628/4885TSHR 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.